CanSinoBIO is a biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & development, manufacturing and commercialization of vaccine products for human use.

康希诺生物

Tianjin CanSino Biotechnology Inc. | 624 followers on LinkedIn. Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

CanSino has established bacterial and cell/viral culture pilot facilities in compliance to the current GMP standard.

Co-founder, Chairman and CEO at CanSino Biologics Inc.

Xuefeng Yu

VP, CanSino

Tao Zhu

Technician at CanSino Biotechnology Inc

Wanyu Zhu

Senior Admin Officer at CanSinoBIO technology Inc.

Sheila Wang

Tianjin CanSino Biotechnology Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

6185

COM:CANSINOTECH

康希诺生物

Last Close

29.15

22/11 08:08

Market Cap

6.49B

Beta: -

Volume Today

1.73M

Avg: -

Filings Not Available